# Critical Evaluation of Chaperone Selectivity Hypotheses
## Hypothesis 1: Co-chaperone Heterogeneity (DNAJB6/DNAJB2)
**Weak Links:**
- The "client code" is descriptive terminology lacking mechanistic detail—how do specific J-protein/HSP70 kinetic differences translate to conformational discrimination?
- DNAJB6 anti-amyloid activity may reflect kinetic suppression of nucleation rather than selective recognition of pre-formed pathogenic seeds
- Overlapping J-protein functionality and redundancy questions whether this provides high-fidelity selectivity
**Counter-Evidence:**
- Germline DNAJB6 mutations cause myofibrillar myopathy (loss-of-function), not gain of specific conformational recognition, suggesting the mechanism is general quality control rather than pathologic selectivity
- No structural data demonstrating differential J-protein binding to distinct conformational states
**Falsifying Experiment:**
- Compare DNAJB6 binding affinity for pre-formed fibrils vs. early-stage oligomers vs. monomers using surface plasmon resonance. If DNAJB6 binds monomers with equal or greater affinity, selectivity is kinetic, not conformational.
**Revised Confidence:** 0.45 (from 0.65)
---
## Hypothesis 2: CK2-Phosphorylation of HSP90α
**Weak Links:**
- CK2 is one of the most pleiotropic kinases in the proteome (thousands of substrates); functional specificity for pathologic conformer recognition is mechanistically implausible
- T115 and S226 are not well-validated as physiologically relevant regulatory sites; literature is correlative rather than mechanistic
- The "allosteric remodeling" claim lacks structural data (HSP90 phosphorylation has been studied primarily on S231 in the middle domain)
**Counter-Evidence:**
- CK2 inhibitors (CX-4945) are in clinical trials for cancer—chronic CK2 inhibition would have pleiotropic effects that confound interpretation
- No evidence that HSP90 phosphorylation state correlates with pathogenic conformer burden in patient samples
**Falsifying Experiment:**
- Test whether CK2 knockdown or CX-4945 treatment alters HSP90 binding to recombinant pathologic tau conformers in vitro. If CK2 inhibition does not change client discrimination, the hypothesis fails.
**Revised Confidence:** 0.30 (from 0.55)
---
## Hypothesis 3: Exposed Amyloidogenic Segments
**Weak Links:**
- HSP70's broad substrate specificity predicts high-affinity binding to any exposed hydrophobic segment—this conflates "prefers misfolded" with "distinguishes pathologic from physiologic misfolded states"
- Does not explain selectivity for disease-causing conformers vs. benign folding intermediates that also expose hydrophobic segments
- Aggregation-prone sequences are shared across many aggregation-prone proteins but are not inherently pathologic
**Counter-Evidence:**
- Transient native-state fluctuations expose hydrophobic segments during normal folding—this predicts HSP70 would "waste" cycles on normal substrates
- No evidence that HSP70 preferentially dissociates from early oligomers (on-pathway to fibrils) vs. late-stage seeds
**Falsifying Experiment:**
- Hydrogen-deuterium exchange mass spec comparing HSP70 binding to A53T vs. wild-type α-synuclein PFFs. If A53T (pathogenic) and WT show equivalent binding, selectivity is low. Test whether HSP70 discriminates between oligomers on the fibril pathway vs. off-pathway aggregates.
**Revised Confidence:** 0.55 (from 0.70)
---
## Hypothesis 4: CHIP-Mediated Ubiquitination
**Weak Links:**
- CHIP recognizes linear degradation motifs (KFERL-like sequences) and HSP70-bound states, not specific conformations—the "conformational discriminator" framing is unsupported
- The "refolding zone" concept lacks kinetic parameters and experimental validation
- If CHIP selectively degrades pathologic conformers, loss-of-function should cause widespread neurodegeneration (not observed in CHIP knockout mice—primary phenotype is cardiac/muscle)
**Counter-Evidence:**
- CHIP knockout mice show selective vulnerability in heart and muscle, not brain (PMID: 15837799)
- CHIP substrates include many non-pathologic clients—this questions specific conformational discrimination
**Falsifying Experiment:**
- Test whether GFP-tagged monomeric α-synuclein (non-pathologic) vs. PFFs produce equivalent HSP70-CHIP complex stability by co-IP. If monomers form equally stable complexes, selectivity is low. Quantify K48-ubiquitin chains on monomeric vs. aggregated species.